AIR Option 1: Technology Translation - Wireless control of distributed and implanted micro infusion pumps

PFI: AIR技术翻译项目致力于翻译首个无线、全可编程、可植入、集成剂量跟踪闭环控制的微型输液泵，填补目前小动物研究给药技术的技术空白。翻译后的技术具有以下独特功能：用于电子实时确认实际输送和剂量量的传感器，能够访问宽动态流量范围的无线操作，以及适合小鼠使用的外形因素，与该市场领域领先的输注技术相比，提供了示范性的性能，效率和功效，无论是否可植入。该项目通过将用于控制输液和跟踪剂量的无线电路集成到一个适合用于微型输液泵的微小形状因素中，从而实现了这一目标，从而形成了一个闭环可植入输液系统的工作原型，将在工作台上进行演示。合作伙伴关系包括史蒂文斯创新中心、维特比学生创新研究所、劳埃德格雷夫创业研究中心和行业合作伙伴（Fluid Synchrony、SAI Infusion Technologies和Charles River），在药物输送技术领域以及商业化、制造和融资的其他方面提供指导，因为它们涉及到将技术转化为可能导致竞争的商业现实的潜力。潜在的经济影响预计将在未来十年改善科学发现和药物开发，这将有助于美国在药物输送技术领域的竞争力。从长远来看，社会影响将是新的疗法、更大的药物疗效、更少的副作用、更好的治疗结果和生活质量，特别是因为它们涉及到这项工作对实现临床闭环输液系统的长期目标的潜在影响。

This PFI: AIR Technology Translation project focuses on translating the first wireless, fully programmable, implantable micro infusion pump with integrated dose tracking for closed-loop control to fill the current technology gap in drug administration technology for small animals research. The translated technology has the following unique features: sensors for electronic real time confirmation of actual delivery and dosed volumes, wireless operation capable of accessing a wide dynamic range of flow rates, and form factor suitable for use in mice that provides exemplary performance, efficiency, and efficacy, when compared to the leading competing infusion technologies, whether implantable or not, in this market space. The project accomplishes this goal by integrating wireless circuitry for controlling infusion and tracking doses into a tiny form factor suitable for use in a miniaturized infusion pump resulting in a working prototype closed-loop implantable infusion system that will be demonstrated at the benchtop. The partnership engages Stevens Center for Innovation, Viterbi Student Institute for Innovation, Lloyd Greif Center for Entrepreneurial Studies, and industry partners (Fluid Synchrony, SAI Infusion Technologies, and Charles River) to provide guidance in the drug delivery technology space and other aspects of commercialization, manufacturing, and financing as they pertain to the potential to translate the technology along a path that may result in a competitive commercial reality. The potential economic impact is expected to be improved scientific discovery and drug development in the next decade, which will contribute to the U.S. competitiveness in the drug delivery technologies space. The societal impact, long term, will be new therapies, greater drug efficacy, reduced side effects, improved treatment outcomes, and quality of life, especially as they relate to the potential impact of this effort on the long term goal of realizing closed-loop clinical infusion systems.